Genedata AG Screener 9 - Used for HTS and HCS Data Analysis at UT Southwestern Medical Center - at SBS 2011
Published: Mar 28, 2011
"Genedata Screener has created a number of efficiencies in the way we manage high-throughput compound and genome-wide siRNA screening, and over the past year we supported more than 50 projects in which Screener played an important role in data analysis and reporting," said Dr. Bruce Posner, director of HTS/RNAi Screening Core and associate professor of the Biochemistry Department at UT Southwestern Medical Center in Dallas.
Optimizing Efficiency and Effectiveness
Pharmaceutical companies, specialized contract research organizations (CROs), and academic screening centers use Genedata Screener's advanced visualization capabilities to accelerate the complete hit-to-lead process. It also features out-of-the-box integration with leading HCS image storage solutions.
Posner's team further uses Genedata Screener's advanced visualization tools to rapidly analyze dose-response curves. Condoseo, which fits thousands of dose-response curves in seconds, is one of five Genedata Screener modules, which work together to process, analyze, and manage data from plate-based screening. Condoseo imports concentration series data, optimizes fits heuristically, and displays results in compound-centric views together with a fit quality rating. Specialized viewers accurately show the distribution of potency and efficacy of all compounds in a global overview of the entire assay with instantaneous drill downs to individual curves. For experiments based on High-Content Screening (HCS) or time-series data, HCS images underlying the data points can be viewed within Condoseo; the same is true for kinetics traces, for example from label-free experiments. All results are stored centrally and can be exported manually or as automatically generated reports.
"Academic research institutions, CROs, and even larger pharmaceutical companies all have cost and time-to-market pressures, which make home-grown and hand-tailored screening solutions no longer sustainable," noted Dr. Othmar Pfannes, CEO of Genedata. "Therefore, Genedata Screener is the off-the-shelf solution of choice that brings together all the workflow support required for high-quality and effective screening - at an affordable price point. Removing the overhead of research data management enables screening centers like Dr. Posner's to focus on identifying those compounds that will lead to effective therapies in conquering all types of cancers, central nervous system diseases, and metabolic disorders."
Mark your calendars for the SBS Genedata Screener 9 Tutorials: Session 1 - "Efficient Analysis of Label-free Data with Genedata Screener Kinetics Analyzer -- March 29 from 4:30pm to 5:30pm; Session 2 - "Scaling Up Your HCS Operations with Genedata Screener High Content Analyzer" - March 31 from 8:00am to 9:00am]
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan, and the US. www.genedata.com
Allison Kurz Genedata Marketing & Communications Phone: +41 61 511 8459 email@example.com
Jackie Thrasivoulos Genedata Public Relations Phone: +1 508 881 3109 firstname.lastname@example.org
Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.